Symbicort is a drug owned by Astrazeneca Lp. It is protected by 33 US drug patents filed from 2013 to 2022. Out of these, 8 drug patents are active and 25 have expired. Based on its patents and exclusivities, its generic launch date is estimated to be Oct 07, 2029. Details of Symbicort's patents and their expiration are given in the table below.

A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Symbicort's patents.

Latest Legal Activities on Symbicort's Patents

Given below is the list of recent legal activities going on the following patents of Symbicort.

Activity	Date	Patent Number
Today's Legal Activities
Expire Patent Critical	29 Apr, 2024	US8143239 (Litigated)
Maintenance Fee Reminder Mailed Critical	13 Nov, 2023	US8143239 (Litigated)
Expire Patent Critical	31 Jul, 2023	US7967011
Expire Patent Critical	03 Apr, 2023	US7897646
Maintenance Fee Reminder Mailed Critical	13 Feb, 2023	US7967011
Maintenance Fee Reminder Mailed Critical	17 Oct, 2022	US7897646
Payment of Maintenance Fee, 4th Year, Large Entity	15 Jun, 2022	US10166247 (Litigated)
Recordation of Patent Grant Mailed Critical	26 Apr, 2022	US11311558 (Litigated)
Patent Issue Date Used in PTA Calculation Critical	26 Apr, 2022	US11311558 (Litigated)
Payment of Maintenance Fee, 8th Year, Large Entity	20 Apr, 2022	US8875699

While patent expiration is one way of estimating the generic date of a drug, if a patent gets invalidated somehow, the generic of the drug may arrive early. Being aware of all relevant patents can help in avoiding legal pitfalls. Given below are details of the litigation history of Symbicort and ongoing litigations to help you estimate the early arrival of Symbicort generic.

Symbicort's Litigations

Symbicort been subject to various legal proceedings, including patent litigations. The earliest legal proceeding was initiated on Jan 09, 2017, against patent number US7759328. The petitioner Complex Innovations, LLC, challenged the validity of this patent, with AstraZeneca AB as the respondent. Click below to track the latest information on how companies are challenging Symbicort's patents.

Patent	Proceeding Filing Date	Status	Respondent	Petitioner
Live updates
US7759328	January, 2017	Institution Denied (24 Jul, 2017)	AstraZeneca AB et al.	Complex Innovations, LLC
US7759328	January, 2017	Terminated-Denied (24 Jul, 2017)	AstraZeneca AB	Complex Innovations, LLC

FDA has granted some exclusivities to Symbicort. Till the time these exclusivities are active, no other company can market a generic or bioequivalent version of Symbicort, regardless of the status of it's patents. These exclusivities hence play a crucial role in delaying the generic launch. Given below are details of the exclusivities granted to Symbicort.

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

Download Report

Several oppositions have been filed on Symbicort's European patents. EP oppositions can significantly impact the timeline for the generic launch of drugs. If an opposition results in the revocation or amendment of a patent, it can shorten the exclusivity period of the original drug. This can lead to an earlier entry of generic versions into the market. To help you estimate the potential early arrival of Symbicort's generic, the next section provides detailed information on ongoing and past EP oppositions related to Symbicort patents.

Symbicort's Oppositions Filed in EPO

Symbicort has faced multiple oppositions in the European Patent Office. The earliest opposition was filed on Nov 25, 2009, by Norton Healthcare Limited. This opposition was filed on patent number EP03703575A. Click below to reveal the latest opposition data.

Application	Filing Date	Opposition Party	Legal Status
Live updates
EP03703575A	Nov, 2009	NORTON HEALTHCARE LIMITED	Revoked

US patents provide insights into the exclusivity only within the United States, but Symbicort is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Symbicort's family patents as well as insights into ongoing legal events on those patents.

Symbicort's Family Patents

Symbicort has patent protection in a total of 41 countries. It's US patent count contributes only to 8.7% of its total global patent coverage. 10 countries have all of their patents expired or invalidated which has opened up potential generic launch opportunities in these countries. Click below to unlock the full patent family tree for Symbicort.

Unlock Global Patents

Generic Launch

About Symbicort

Symbicort is a drug owned by Astrazeneca Lp. It is used for managing and treating chronic respiratory conditions like COPD and asthma. Symbicort uses Budesonide; Formoterol Fumarate Dihydrate as an active ingredient. Symbicort was launched by Astrazeneca in 2006.